HCC1806 Xenograft Model Service for Breast Cancer

The HCC1806 xenograft model provides a robust and aggressive in vivo platform essential for evaluating novel therapeutic candidates and uncovering mechanistic insights in triple-negative breast cancer (TNBC) research. Alfa Cytology offers specialized, end-to-end HCC1806 xenograft model services, combining optimized study protocols with extensive oncology expertise to streamline your preclinical drug development pipeline.

Overview of HCC1806 Xenograft Model for Breast Cancer

The HCC1806 cell line is a highly characterized human mammary carcinoma model that represents the basal-like, triple-negative breast cancer (TNBC) molecular subtype. Isolated from a primary acantholytic squamous cell carcinoma of the breast, this model is molecularly defined by the absence of estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor 2 (HER2) amplification. This distinctive clinical background makes HCC1806 a frontline tool for therapeutic research aimed at overcoming the challenges of chemotherapy resistance and identifying targeted small-molecule inhibitors or immunotherapies for refractory breast cancers.

When established in vivo as a xenograft in immunocompromised mice, HCC1806 cells form tumors characterized by rapid growth kinetics and high vascularization. This aggressive proliferation closely mimics the clinical progression of poorly differentiated, high-grade TNBC.

Fig 1. Cellular uptake of 18F-fluciclovine and glutaminase activity in TNBC and estrogen receptor--positive breast cancer cells. (Zhou R, et al., 2023)

Cell Line Information: HCC1806

The HCC1806 cell line demonstrates a stable epithelial morphology and preserves its genomic profile reliably across multiple in vitro passages and in vivo translational cycles.

Alfa Cytology is dedicated to upholding the highest standards of scientific precision and data reproducibility in every in vivo project we manage. Our oncology experts utilize strictly authenticated cell banks and optimized laboratory protocols to guarantee that the phenotypic identity of the HCC1806 model remains stable throughout the life of your study.

Our Services

Alfa Cytology provides a fully integrated, turnkey solution for the HCC1806 Xenograft Model Service. Our dedication to quality begins with rigorous cell line authentication and mycoplasma testing. We manage every critical step of the preclinical journey—from standardized cell preparation, orthotopic or subcutaneous inoculation, in-life monitoring, to comprehensive endpoint analyses including IHC and PK/PD profiling. Leveraging our expertise in triple-negative breast cancer models, we deliver robust data packages tailored to accelerate your drug discovery programs.

Workflow of HCC1806 Xenograft Model Construction

Alfa Cytology follows a scientifically rigorous and meticulously standardized workflow to construct the HCC1806 xenograft model:

• Cell Culture & QC: HCC1806 cells are expanded in specialized growth media during their exponential growth phase. Comprehensive quality control, including STR profiling and mycoplasma testing, is performed to ensure high viability and phenotypic identity before inoculation.
• Host Selection & Acclimatization: Standardized immunocompromised mice are selected based on the experimental design and allowed to acclimate to our controlled facility parameters to achieve baseline physiological stability.
• Standardized Inoculation: A highly viable, calibrated suspension of HCC1806 cells is prepared, frequently supplemented with a biological matrix carrier to enhance initial cell retention. The mixture is precisely injected in vivo via subcutaneous or orthotopic mammary fat pad routes.
• Longitudinal Monitoring: Following model establishment, tumor growth and animal weights are systematically tracked using high-precision digital calipers to construct reliable growth curves while strictly adhering to animal welfare guidelines.
• Stratification & Dosing: Once the tumors reach a predetermined, statistically optimal volume range, animals are randomized into balanced treatment and control cohorts to ensure uniform group parameters prior to the start of dosing protocols.

Fig 2. HCC1806 Xenograft Model Construction Workflow

Case Study - HCC1806 Xenograft Model Development

In a recent preclinical trial conducted at Alfa Cytology, the HCC1806 xenograft model was successfully utilized to evaluate the therapeutic efficacy of a novel small-molecule inhibitor targeting the DNA damage response in TNBC. Our technical team achieved highly reproducible tumor engraftment and exceptionally uniform growth kinetics across all study arms, facilitating an unobstructed and definitive assessment of therapeutic efficacy. The in vivo study demonstrated significant, dose-dependent tumor growth inhibition in the treatment group compared to the vehicle control.

Why Choose Alfa Cytology?

Choosing the right partner for your triple-negative breast cancer research is critical for generating high-quality, reproducible data. Alfa Cytology stands out by offering specialized expertise and high-standard preclinical services:

• TNBC Modeling Specialization: Extensive track record in establishing and validating aggressive, receptor-negative human mammary tumor models.
• Technical Reproducibility: Refined inoculation protocols that ensure uniform tumor growth curves and minimize experimental variation.
• Comprehensive Multi-Omic Endpoints: Full capability for downstream analysis, including histopathology, digital caliper tracking, IHC tumor profiling, and PK/PD tissue analysis.
• Rigorous Data Integrity: Strict commitment to scientific transparency, data security, and international research standards throughout the study lifecycle.

Contact Us

Are you ready to accelerate your triple-negative breast cancer drug discovery program with the robust HCC1806 xenograft platform? The senior scientific team at Alfa Cytology is fully equipped to design and execute a tailored study protocol that directly addresses your unique research questions. Please reach out to us today to speak directly with an oncology specialist, or contact us to receive a customized project consultation and detailed quotation.

For research use only. Not intended for any clinical use.